From promise to people. Our mission is to pioneer a new branch of medicine based on the directed differentiation and transplant of allogeneic cells to patients CORPORATE OVERVIEW MARCH 24, 2026 NYSE AMERICAN: LCTX lineagecell.com Forward-Looking Statements Cell manufacturing and transplant technology 7 Cell types in development Highly Differentiated Allogeneic product candidates 2 Active clinical trials >200 Cell types as potential targets This presentation is for informational purposes only and is not an o ...

Core Insights - Lineage Cell Therapeutics is advancing its OpRegen program for dry age-related macular degeneration (AMD) and has seen significant partner activity, including Roche and Genentech opening 10 new clinical sites for the GALE Phase 2a study, now totaling 17 sites, which is viewed as a positive indicator for future trials [1][5][6] - The company reported a cash position of $55.8 million, with expectations to fund operations into Q2 2028, bolstered by recent warrant exercises and milestone payments [5][19] - Lineage is focusing on scalable production of undifferentiated cells through its AlloSCOPE platform, which aims to address manufacturing challenges in cell therapy [4][7][17] Financial Performance - For Q4, Lineage reported total revenue of approximately $6.6 million and a net income of $0.9 million, compared to a net loss of $3.3 million in the same period last year [20] - The full-year revenue was reported at $14.6 million, with a net loss of $63.5 million, reflecting an increase in losses primarily due to non-cash charges [21][22] - The company’s cash runway has been extended due to a $21 million ATM block trade and other financial maneuvers, allowing for continued operational funding [19][22] Program Updates - The OpRegen program is highlighted as a critical case study, with analyses suggesting that a single dose could provide visual improvement for at least three years [2][5] - Lineage is also progressing with its OPC1 program for spinal cord injury, currently enrolling patients in a safety trial, and has treated its first chronic SCI patient [12][13] - The Resonance program for hearing loss has secured funding partnerships, achieving its 2025 objective and demonstrating the potential for new intellectual property [14][15] Manufacturing Strategy - The AlloSCOPE platform is central to Lineage's manufacturing strategy, focusing on scalable and consistent production of pluripotent cells [4][7] - The company has established GMP master and working cell banks, aiming to produce clinical-grade products for trials [7][8] - Lineage is addressing the supply and scale issues in islet cell transplants, with a focus on generating billions of undifferentiated pluripotent stem cells [11][17]

Earnings Call InsightsLineage extends cash runway into Q2 2028 while advancing OpRegen and new pipeline programsMar. 05, 2026 9:46 PM ETLineage Cell Therapeutics, Inc. (LCTX) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Lineage Cell Therapeutics (LCTX) Q4 2025 Management View CEO Brian Culley opened the call highlighting recent warrant exercises that have further extended the company's cash runway and announced a positive result for the initial go/no-go development milestoneNewsl ...

Lineage Cell (LCTX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +100.00%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.02 per share when it actually produced a loss of $0.13, delivering a surprise of -550%.Over the last four quarters, the company ...

Lineage Cell Therapeutics (NYSEAM:LCTX) Q4 2025 Earnings call March 05, 2026 04:30 PM ET Company ParticipantsBrian Culley - CEOIoana Hone - Head of Investor RelationsJill Howe - CFOJoseph Pantginis - Managing Director of Equity ResearchMayank Mamtani - Senior Managing Director and Group Head of HealthcareConference Call ParticipantsAlbert Lowe - Senior Research AnalystJack Allen - Senior Research AnalystNone - AnalystOperatorWelcome to the Lineage Cell Therapeutics 3rd Quarter 2025 Conference Call. At this ...

Financial Data and Key Metrics Changes - The reported net loss for the full year 2025 is approximately $63.5 million, which is $45 million higher than in 2024, primarily due to non-cash charges linked to rising stock prices and an asset impairment charge [31][39] - Total revenues for the fourth quarter were approximately $6.6 million, a net increase of $3.7 million compared to the same period in 2024, driven by higher collaboration revenue from Roche [33] - Total operating expenses for the fourth quarter were $13.2 million, an increase of $5.2 million compared to the same period in 2024 [34] Business Line Data and Key Metrics Changes - R&D expenses for the fourth quarter were $8.2 million, an increase of $4.8 million compared to the same period in 2024, driven by costs associated with the OpRegen program and other preclinical programs [34][38] - G&A expenses for the fourth quarter were approximately $4.8 million, an increase of $0.4 million compared to the same period in 2024, primarily due to personnel costs [34] Market Data and Key Metrics Changes - The company has achieved a significant milestone under its Roche Genentech alliance, which has led to the opening of 10 new clinical sites for the GALE study in the past nine months, indicating positive forward progress [8][14] Company Strategy and Development Direction - The company is focused on delivering the next wave of innovation in cell therapy, particularly in areas outside of oncology, with a strong emphasis on the OpRegen program for dry AMD [5][7] - The AlloSCOPE platform is being utilized to scale pluripotent cells for various applications, aiming to address challenges in manufacturing and supply for cell therapies [10][22] - A new research initiative in type one diabetes has been announced, with the company achieving its initial go/no-go development milestone, indicating a commitment to solving supply issues in islet cell transplants [23][24] Management's Comments on Operating Environment and Future Outlook - Management remains confident in the potential for OpRegen to drive positive clinical outcomes and is encouraged by the commitment from partners [41] - The company is optimistic about the scalability of its manufacturing processes and the potential to develop additional cell-based products [12][29] Other Important Information - The company has a cash position of $55.8 million as of December 31, 2025, which, along with recent warrant exercises, is expected to support operations into Q2 of 2028 [32] - The company has identified a significant opportunity in the islet cell transplant space, focusing on overcoming supply challenges to create a commercially viable product [24][28] Q&A Session Summary Question: Strategic business development with various cell types and AlloSCOPE - The company is leveraging its AlloSCOPE platform to generate a basket of assets and is mindful of cost of capital and risk in its business development strategy [44][46] Question: Rate-limiting steps for islet cell component scale-up - The transition from half-liter to larger scales presents challenges, but the company is optimistic about achieving control in lower mid-liter scales [47][49] Question: Timing of functional measures in OPC1 program - The OPC1 study is primarily a safety and performance study, with functional assessments occurring at one year rather than earlier [61][62] Question: Potential for four-year data on OpRegen - The company is excited about the durability of benefits seen in OpRegen but does not have information on the plans for four-year data from its partner [59] Question: Learnings from islet cell research and Roche partnership - The inverted risk approach is being applied to the islet cell initiative, with insights gained from various programs contributing to the development strategy [73][74]

Financial Data and Key Metrics Changes - The reported net loss for the full year 2025 is approximately $63.5 million, which is $45 million higher than in 2024, primarily due to non-cash charges linked to rising stock prices and an asset impairment charge [31][38]. - Total revenues for the fourth quarter were approximately $6.6 million, a net increase of $3.7 million compared to the same period in 2024, driven by higher collaboration revenue from Roche [33]. - Total operating expenses for the fourth quarter were $13.2 million, an increase of $5.2 million compared to the same period in 2024 [34]. Business Line Data and Key Metrics Changes - R&D expenses for the fourth quarter were $8.2 million, an increase of $4.8 million compared to the same period in 2024, primarily driven by costs associated with the OpRegen program [34]. - G&A expenses for the fourth quarter were approximately $4.8 million, an increase of $0.4 million compared to the same period in 2024, mainly due to personnel costs [34]. Market Data and Key Metrics Changes - The company has a cash position of $55.8 million as of December 31, 2025, which, along with proceeds from warrant exercises, is expected to support operations into Q2 of 2028 [32]. - The company has approximately $32 million remaining in underlying warrants priced at $0.91 per share, which could be accelerated if Roche or Genentech advance OpRegen into clinical trials [32]. Company Strategy and Development Direction - The company is focused on leveraging its AlloSCOPE platform to develop scalable, cost-effective cell therapies, with a particular emphasis on addressing the challenges of islet cell transplants for diabetes [24][25]. - The company aims to create a pipeline of differentiated cell-based products, applying lessons learned from existing programs to new initiatives [12][24]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of the OpRegen program to drive positive clinical outcomes in dry AMD, supported by the commitment from Roche [40]. - The company is optimistic about the advancements in its manufacturing capabilities and the potential for new partnerships to fund ongoing development [40]. Other Important Information - The company achieved its first milestone under the Roche collaboration, receiving a $5 million payment, which highlights its contributions to the program [16]. - The company is expanding its research initiatives, including a new focus on type one diabetes, which addresses significant challenges in islet cell transplantation [24][25]. Q&A Session Summary Question: Strategic development of various cell types and AlloSCOPE - Management highlighted the importance of generating new assets that can be partnered early to optimize returns on invested capital [44][46]. Question: Rate-limiting steps in islet cell component scaling - Management noted that transitioning from half-liter to larger scales presents challenges, but they are optimistic about the control achieved at smaller scales [47][49]. Question: Visibility on Roche's GALE study delivery methods - Management provided insights into different delivery methods being tested by Roche, emphasizing the surgical optimization nature of the study [50][52]. Question: Timing of functional measures in the OPC1 program - Management clarified that the OPC1 study is primarily a safety and performance study, with functional assessments occurring at specific intervals [60][61]. Question: Capacity for OpRegen in potential phase 3 trials - Management did not provide specific capacity details but indicated that they are prepared for large-scale trials if necessary [78].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE CARLSBAD, CA – March 5, 2026 - Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical- stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today reported its fourth quarter and full year 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these ...

Core Insights - Lineage Cell Therapeutics has received a novel induced pluripotent stem cell (iPSC) line with hypoimmunity edits from Factor Bioscience, marking a significant milestone in their strategic collaboration [1][2] - The new iPSC line is designed to support non-immune privileged and/or non-HLA matched indications, with specific genetic edits aimed at reducing immunogenicity and enhancing clinical differentiation [1][2] - Lineage plans to leverage this new technology to broaden its cell therapy platform and develop novel product candidates, particularly in the field of retinal cell transplantation [2] Company Overview - Lineage Cell Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic cell therapies for serious medical conditions, utilizing a proprietary cell-based technology platform [3][4] - The company's pipeline includes several therapies, such as OpRegen for age-related macular degeneration, OPC1 for spinal cord injuries, and others targeting auditory neuropathy and Type 1 Diabetes [4] Collaboration Details - The partnership with Factor Bioscience aims to combine manufacturing capabilities with advanced cell engineering technologies to create superior product candidates [2] - The agreement allows Lineage to obtain an exclusive license for the novel gene-edited cell line for preclinical, clinical, and commercial purposes, contingent on further performance criteria and testing outcomes [1][2]